/RNXT
RNXT Stock - RenovoRx, Inc.
Healthcare|BiotechnologyNASDAQ
$0.93+3.33%
+$0.03 (+3.33%) • Dec 19
53
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.19
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.68
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $1.02
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for RNXT
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$0.92 – $0.94
TARGET (TP)$1.07
STOP LOSS$0.86
RISK/REWARD1:2.0
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta1.29
52W High$1.69
52W Low$0.70
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $43,000 | N/A | N/A | N/A | N/A |
| Gross Profit | $43,000 | N/A | N/A | N/A | N/A |
| Gross Margin | 100.0% | N/A | N/A | N/A | N/A |
| Operating Income | $-10,970,000 | $-11,396,000 | $-9,950,000 | $-5,671,000 | $-3,204,000 |
| Net Income | $-8,814,000 | $-10,232,000 | $-9,889,000 | $-6,324,000 | $-3,798,000 |
| Net Margin | -20497.7% | N/A | N/A | N/A | N/A |
| EPS | $-0.37 | $-0.50 | $-0.54 | $-0.40 | $-0.25 |
Company Overview
RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of solid tumors. Its lead product candidate is RenovoGem, a drug and device combination consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer. RenovoRx, Inc. was founded in 2009 and is headquartered in Los Altos, California.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
RNXTBeat Rate
53%
Last 17 quarters
Avg Surprise
+4.7%
EPS vs Estimate
Beats / Misses
9/4
4 met exactly
Latest EPS
$-0.08
Q4 2025
EPS Surprise History
Q2 24
+43.3%
$-0.17vs$-0.30
Q2 24
+50.0%
$-0.07vs$-0.14
Q3 24
0.0%
$-0.10vs$-0.10
Q4 24
+16.7%
$-0.10vs$-0.12
Q1 25
+7.7%
$-0.12vs$-0.13
Q2 25
0.0%
$-0.08vs$-0.08
Q3 25
0.0%
$-0.08vs$-0.08
Q4 25
0.0%
$-0.08vs$-0.08
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Mar 30, 2026 | $-0.08 | — | — | — |
Q4 2025 | Nov 13, 2025 | $-0.08 | $-0.08 | 0.0% | = MET |
Q3 2025 | Aug 14, 2025 | $-0.08 | $-0.08 | 0.0% | = MET |
Q2 2025 | May 15, 2025 | $-0.08 | $-0.08 | 0.0% | = MET |
Q1 2025 | Mar 31, 2025 | $-0.13 | $-0.12 | +7.7% | ✓ BEAT |
Q4 2024 | Nov 13, 2024 | $-0.12 | $-0.10 | +16.7% | ✓ BEAT |
Q3 2024 | Aug 13, 2024 | $-0.10 | $-0.10 | 0.0% | = MET |
Q2 2024 | May 10, 2024 | $-0.14 | $-0.07 | +50.0% | ✓ BEAT |
Q2 2024 | Apr 1, 2024 | $-0.30 | $-0.17 | +43.3% | ✓ BEAT |
Q4 2023 | Nov 13, 2023 | $-0.30 | $-0.27 | +10.0% | ✓ BEAT |
Q3 2023 | Aug 16, 2023 | $-0.25 | $-0.22 | +12.0% | ✓ BEAT |
Q2 2023 | May 15, 2023 | $-0.25 | $-0.36 | -44.0% | ✗ MISS |
Q1 2023 | Mar 2, 2023 | $-0.26 | $-0.23 | +11.5% | ✓ BEAT |
Q4 2022 | Nov 14, 2022 | $-0.27 | $-0.24 | +11.1% | ✓ BEAT |
Q3 2022 | Aug 15, 2022 | $-0.26 | $-0.29 | -11.5% | ✗ MISS |
Q2 2022 | May 16, 2022 | $-0.25 | $-0.33 | -32.0% | ✗ MISS |
Q1 2022 | Mar 30, 2022 | $-0.18 | $-0.12 | +33.3% | ✓ BEAT |
Q4 2021 | Nov 15, 2021 | $-0.21 | $-0.27 | -28.6% | ✗ MISS |
Q3 2021 | Aug 27, 2021 | — | $-0.08 | — | — |
Q1 2021 | Mar 31, 2021 | — | $-0.07 | — | — |
Latest News
RenovoRx Q3 EPS $(0.08), Inline, Sales $266.000K Miss $405.333K Estimate
📉 NegativeBenzinga•Nov 13, 2025, 09:11 PM
RenovoRx Completes First Registry-Eligible Patient Procedure In PanTheR Post-Marketing Registry Study At University Of Vermont Cancer Center
📈 PositiveBenzinga•Sep 25, 2025, 12:32 PM
RenovoRx Revenue Jumps 28 Percent in Q2
📈 PositiveThe Motley Fool•Aug 14, 2025, 10:48 PM
Frequently Asked Questions about RNXT
What is RNXT's current stock price?
RenovoRx, Inc. (RNXT) is currently trading at $0.93 per share. The stock has moved +3.33% today.
What is the analyst price target for RNXT?
No analyst price targets are currently available for this stock.
What sector is RenovoRx, Inc. in?
RenovoRx, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is RNXT's market cap?
RenovoRx, Inc. has a market capitalization of $0.03 billion, making it a small-cap company.
Does RNXT pay dividends?
No, RenovoRx, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorANVS
Annovis Bio, Inc.
$3.65
Mkt Cap: $0.1B
BCAB
BioAtla, Inc.
$0.75
Mkt Cap: $0.0B
CALC
CalciMedica, Inc.
$6.35
Mkt Cap: $0.1B
CELU
Celularity Inc.
$1.45
Mkt Cap: $0.0B
ELUT
Elutia Inc.
$0.59
Mkt Cap: $0.0B
LTRN
Lantern Pharma Inc.
$3.26
Mkt Cap: $0.0B
MAIA
MAIA Biotechnology, Inc.
$1.22
Mkt Cap: $0.0B
PYPD
PolyPid Ltd.
$3.97
Mkt Cap: $0.0B
RVPH
Reviva Pharmaceuticals Holdings, Inc.
$0.60
Mkt Cap: $0.0B
TVRD
Tvardi Therapeutics, Inc.
$3.98
Mkt Cap: $0.0B
Explore stocks similar to RNXT for comparison